Literature DB >> 22453141

MicroRNAs and human cancer.

E G Nikitina1, L N Urazova, V N Stegny.   

Abstract

MicroRNAs (miRNAs) are a recently discovered family of short non-coding RNA molecules of about 19-24 nucleotides in length that are involved in regulation of gene expression. These small molecules have been found to regulate genes involved in diverse biological processes such as cell proliferation, development, differentiation, apoptosis and others. MiRNAs regulate gene expression at the post-transcriptional level either by inhibition of the target (mRNA) or by its destruction. Recent studies have shown that mRNA deregulation is a basic problem in studying pathogenesis of many malignant tumors. It has been recently shown that miRNAs are able to regulate thousands of target genes simultaneously. Thus, the key role of miRNA in carcinogenesis reveals a new layer in the molecular architecture of cancer. Patterns of altered miRNA expression in cancer may serve as molecular biomarkers for tumor diagnosis, prognosis of disease-specific outcomes, and prediction of therapeutic responses. Furthermore, miRNAs may serve as specific targets of new gene therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22453141

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  32 in total

1.  Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas.

Authors:  J Sperveslage; M Hoffmeister; T Henopp; G Klöppel; B Sipos
Journal:  Endocrine       Date:  2014-02-18       Impact factor: 3.633

2.  Decreased expression of serum miR-647 is associated with poor prognosis in gastric cancer.

Authors:  Huan Ma; Peijun Wang; Yuan Li; Yan Yang; Shuhui Zhan; Yuqiang Gao
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

Review 3.  Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: An update and review.

Authors:  Ya-Kai Huang; Jian-Chun Yu
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

4.  MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma.

Authors:  Feng Liu; Linfeng Wu; Anping Wang; Yajun Xu; Xiaodong Luo; Xing Liu; Yi Hua; Deying Zhang; Shengde Wu; Tao Lin; Dawei He; Guanghui Wei; Shanwen Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

5.  MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor.

Authors:  Jianqiao Luo; Caidan Zhu; Hongya Wang; Li Yu; Jianwei Zhou
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

6.  miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer.

Authors:  Pablo Letelier; Patricia García; Pamela Leal; Héctor Álvarez; Carmen Ili; Jaime López; Jonathan Castillo; Priscilla Brebi; Juan Carlos Roa
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.

Authors:  Manchao Zhang; Longzhu Piao; Jharna Datta; James C Lang; Xiujie Xie; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Mol Cancer Ther       Date:  2015-07-30       Impact factor: 6.261

8.  Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.

Authors:  Jena Hudson; Eric Duncavage; Anna Tamburrino; Paolo Salerno; Liqiang Xi; Mark Raffeld; Jeffrey Moley; Rebecca D Chernock
Journal:  Exp Mol Pathol       Date:  2013-05-16       Impact factor: 3.362

9.  MicroRNA-155 expression as a prognostic factor in patients with gallbladder carcinoma after surgical resection.

Authors:  Xue-Lin Zhang; Jun-Hong Chen; Cheng-Kun Qin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 10.  Exercise: putting action into our epigenome.

Authors:  Joshua Denham; Francine Z Marques; Brendan J O'Brien; Fadi J Charchar
Journal:  Sports Med       Date:  2014-02       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.